Brian Timothy Hess

Title
InstitutionMedical University of South Carolina
DepartmentHematology/Oncology
AddressP.O. Box MSC 635
Walton Research Building - 39 Sabin Street
Phone843-792-4271
Fax843-792-0644
vCardDownload vCard

    Collapse Overview 
    Collapse keywords
    Cancer/Leukemia

    Collapse ORNG Applications 
    Collapse studies/trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Sawalha Y, Goyal S, Switchenko JM, Romancik JT, Kamdar M, Greenwell IB, Hess BT, Isaac KM, Portell CA, Mejia Garcia AV, Goldsmith SR, Grover NS, Riedell PA, Karmali R, Burkart M, Buege M, Akhtar OS, Torka P, Kumar A, Hill BT, Kahl BS, Cohen JB. A Multicenter Analysis of the Outcomes with Venetoclax in Patients with Relapsed Mantle Cell Lymphoma. Blood Adv. 2023 Feb 21. PMID: 36809796.
      Citations:    Fields:    
    2. Schandl CA, Mazzoni S, Znoyko I, Nahhas GJ, Chung D, Ding Y, Hess B, Wolff DJ. Novel high-risk acute myeloid leukemia subgroup with ERG amplification and Biallelic loss of TP53. Cancer Genet. 2023 04; 272-273:23-28. PMID: 36657266.
      Citations:    Fields:    Translation:Humans
    3. Davis JA, Granger K, Roubal K, Smith D, Gaffney KJ, McGann M, Cendagorta A, Thurlapati A, Herbst A, Hendrickson L, Hashmi H, Hess BT. Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies. Blood. 2023 01 12; 141(2):200-203. PMID: 36332185; PMCID: PMC9636601.
      Citations: 8     Fields:    Translation:HumansCells
    4. Hess BT, Giri A, Park Y, Patel KK, Link BK, Nowakowski GS, Maliske SM, Fortin S, Chavez JC, Saeed H, Hill BT, Mejia Garcia AV, Maddocks KJ, Hanel W, Wagner-Johnston ND, Messmer MR, Kahl BS, Watkins M, Alderuccio JP, Lossos IS, Nathan S, Orellana-Noia VM, Portell CA, Landsburg DJ, Ayers EC, Castillo JJ. Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study. Am J Hematol. 2023 02; 98(2):300-308. PMID: 36588409.
      Citations: 1     Fields:    Translation:Humans
    5. Davis JA, Misniakiewicz J, Hendrickson L, McGann M, Herbst A, Hess BT. Gastric adenocarcinoma following CD19-directed chimeric antigen receptor T cell therapy. Ann Hematol. 2023 02; 102(2):461-462. PMID: 36385650.
      Citations:    Fields:    Translation:Humans
    6. Davis JA, Gaffney KJ, McGann M, Smith D, Edwards K, Baldino E, Bakos K, Butcher C, Greenwell B, Hess BT, Hashmi H. Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy. Clin Lymphoma Myeloma Leuk. 2023 01; 23(1):e14-e18. PMID: 36319568.
      Citations: 1     Fields:    Translation:Humans
    7. Zurko JC, Nizamuddin I, Epperla N, David KA, Cohen JB, Moyo T, Ollila TA, Hess BT, Roy I, Ferdman R, Liu J, Chowdhury SM, Romancik JT, Bhansali RS, Harris EI, Sorrell M, Masel R, Kittai AS, Denlinger N, Sigmund AM, Fitzgerald LA, Galvez C, Ma S, Winter JN, Pro B, Gordon LI, Danilov AV, Stephens DM, Shah NN, Kenkre VP, Barta SK, Torka P, Shouse G, Karmali R. Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL. Blood Adv. 2022 Sep 12. PMID: 36094847.
      Citations:    Fields:    
    8. Alderuccio JP, Ai WZ, Radford J, Solh M, Ardeshna KM, Lunning MA, Hess BT, Zinzani PL, Stathis A, Carlo-Stella C, Hamadani M, Kahl BS, Ungar D, Kilavuz T, Yu E, Qin Y, Caimi PF. Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. Blood Adv. 2022 08 23; 6(16):4736-4739. PMID: 35790100; PMCID: PMC9631657.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    9. McGann M, Davis JA, Gaffney KJ, Smith D, Edwards K, Hess BT, Hashmi H, McGann M, Davis JA, Gaffney KJ, Smith D, Edwards K, Hess BT, Hashmi H. Real-World Experience and Optimization of Outpatient Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2022 09; 28(9):583-585. PMID: 35781100.
      Citations: 1     Fields:    Translation:Humans
    10. Hess B, Kalmuk J, Znoyko I, Schandl CA, Wagner-Johnston N, Mazzoni S, Hendrickson L, Chiad Z, Greenwell IB, Wolff DJ, Hess B, Kalmuk J, Znoyko I, Schandl CA, Wagner-Johnston N, Mazzoni S, Hendrickson L, Chiad Z, Greenwell IB, Wolff DJ. Clinical utility of chromosomal microarray in establishing clonality and high risk features in patients with Richter transformation. Cancer Genet. 2022 01; 260-261:18-22. PMID: 34808593.
      Citations:    
    11. Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA, Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA. Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clin Cancer Res. 2021 06 15; 27(12):3339-3350. PMID: 33832946; PMCID: PMC8197753.
      Citations:    
    12. Ayers EC, Li S, Medeiros LJ, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner-Johnston ND, Karmali R, Behdad A, Fakhri B, Kahl BS, Churnetski MC, Cohen JB, Reddy NM, Modi D, Ramchandren R, Howlett C, Leslie LA, Cytryn S, Diefenbach CS, Faramand R, Chavez JC, Olszewski AJ, Liu Y, Barta SK, Mukhija D, Hill BT, Ma H, Amengual JE, Nathan S, Assouline SE, Orellana-Noia VM, Portell CA, Chandar A, David KA, Giri A, Hess BT, Landsburg DJ, Ayers EC, Li S, Medeiros LJ, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner-Johnston ND, Karmali R, Behdad A, Fakhri B, Kahl BS, Churnetski MC, Cohen JB, Reddy NM, Modi D, Ramchandren R, Howlett C, Leslie LA, Cytryn S, Diefenbach CS, Faramand R, Chavez JC, Olszewski AJ, Liu Y, Barta SK, Mukhija D, Hill BT, Ma H, Amengual JE, Nathan S, Assouline SE, Orellana-Noia VM, Portell CA, Chandar A, David KA, Giri A, Hess BT, Landsburg DJ. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer. 2020 01 15; 126(2):293-303. PMID: 31568564.
      Citations:    
    13. Bosanquet JP, Bade BC, Zia MF, Karo A, Hassan O, Hess BT, Dabbagh O, Bosanquet JP, Bade BC, Zia MF, Karo A, Hassan O, Hess BT, Dabbagh O. Patients with venous thromboembolism appear to have higher prevalence of obstructive sleep apnea than the general population. Clin Appl Thromb Hemost. 2011 Nov-Dec; 17(6):E119-24. PMID: 21159707.
      Citations:    
    Hess's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (59)
    Explore
    _
    Co-Authors (5)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _